| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity. Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate). Hydroxytyrosol is potent against CSC phenotypes. Mechanisms: -Blocks EMT, reducing transition into CSC-like states -Inhibits Notch signaling -Reduces CD44+ / CD24– CSC markers -Inhibits hypoxia-driven stemness (HIF-1α suppression) Hydroxytyrosol is especially active in: -Breast CSCs -Melanoma CSC-like cells -Gastric CSC models Hydroxytyrosol (HT) — Cancer-Relevant Pathways
TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)
TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes
TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 4637- | HT, | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells |
| - | in-vitro, | Nor, | RWPE-1 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 |
| 4638- | HT, | Hydroxytyrosol induces apoptosis in human colon cancer cells through ROS generation |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | 1- |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:376 Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid